Hosted on MSN

JP Morgan Upgrades Recursion Pharmaceuticals (RXRX)

Fintel reports that on December 17, 2025, JP Morgan upgraded their outlook for Recursion Pharmaceuticals (NasdaqGS:RXRX) from Neutral to Overweight. Analyst Price Forecast Suggests 37.89% Upside As of ...
Hosted on MSN

JPMorgan boosts rating on Recursion Pharmaceuticals (RXRX) amid AI-driven drug pipeline

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from a Neutral ...
Forbes

AG1 Review: Is It Worth Using?

Sarah is an experienced writer and editor enthusiastic about helping readers live their healthiest and happiest lives. Before joining Forbes Health, Sarah worked as a writer for various digital ...